iCAD, Inc.
4 Townsend West
Suite 17
Nashua
New Hampshire
03063
United States
Tel: 603-882-5200
Fax: 603-880-3843
Website: http://www.icadmed.com/
335 articles about iCAD, Inc.
-
iCAD Launches New Initiatives Leveraging Unique Capabilities of its Robust Product Portfolio to Reduce Health Care System Pressures During the COVID-19 Pandemic
3/23/2020
ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog
-
iCAD Reports Fourth Quarter and Full-Year 2019 Financial Results
2/27/2020
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment
-
Clinical Catch-Up: February 10-14
2/17/2020
It was a very busy week for clinical trial news. Here’s a look. -
UPDATE -- iCAD to Report Fourth Quarter 2019 Financial Results on Thursday, February 27
2/13/2020
NASHUA, N.H., Feb. 13, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2019, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, February 27. Thursday, February 27th @ 4:30pmET Domestic: 877-407-0784 International: 201-689
-
iCAD to Participate in the 40th Annual Cowen Healthcare Conference
2/12/2020
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the 40th Annual Cowen Healthcare Conference, taking place March 2-4, 2020 in Boston, MA.
-
iCAD Showcases Technology for Cancer “Discovery to Recovery” including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai
1/27/2020
iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer
-
iCAD Appoints Nathaniel Dalton to its Board of Directors
1/13/2020
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced Nathaniel Dalton was appointed to its Board of Directors.
-
iCAD to Showcase Leading Breast Health Solutions Suite Including Expanded ProFound AI™ Platform at RSNA Annual Meeting
12/2/2019
Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time
-
iCAD to Participate at the Cannacord Genuity Medtech & Diagnostics Forum
11/18/2019
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Canaccord Genuity MedTech & Diagnostics Forum, taking place Thursday, November 21st in New York City.
-
iCAD Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2019
10/30/2019
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions reported its financial and operating results for the three and nine months ended September 30, 2019.
-
iCAD Reports Strong Momentum of ProFound AI™, its Artificial Intelligence-Based Solution for Digital Breast Tomosynthesis
3/14/2019
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported strong adoption of its latest deep-learning, cancer detection software solution for digital breast tomosynthesis, ProFound AI™.
-
BioSpace Movers and Shakers: Jan. 4
1/4/2019
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more. -
Sanford Health Announces Adoption of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment Medical facility becomes first in South Dakota to offer intraoperative radiation therapy
10/3/2018
iCAD, Inc. today announced the availability of the company’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at Sanford USD Medical Center.
-
iCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer Treatment
12/7/2017
The analysis demonstrated that IORT could result in direct cost savings for the U.S. healthcare system of more than $630 million over the lifetime of patients diagnosed annually with early-stage breast cancer.
-
iCAD’s PowerLook Tomo Detection Experiences Growing Adoption
11/27/2017
This efficiency enables users to streamline workflow and supports faster, more confident detection of breast cancer.
-
iCAD Reports Third Quarter 2017 Financial Results
11/9/2017
Total revenue of $7.0 million, up 17% year-over-year.
-
iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017”
11/9/2017
Best of ASTRO meeting recognizes most relevant and highly influential research at ASTRO 2017.
-
iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8
11/1/2017
The company will release financial results for the three and nine months ended September 30, 2017 after the close of the market.
-
iCAD Announces Approval Of Xoft Axxent Balloon Applicators By China Food & Drug Administration For Treatment Of Early-Stage Breast Cancer
9/5/2017
-
iCAD Announces Approval Of Xoft Axxent Balloon Applicators By China Food & Drug Administration For Treatment Of Early-Stage Breast Cancer
8/30/2017